Treatment of prostate cancer by hypofractionated radiotherapy
Özet
Technological advances in radiation therapy delivery have permitted the use of high dose per fraction radiotherapy for early stage prostate cancer. Level I evidence supporting the safety and efficasy of hypofractionated radiotherapy is evolving. Moderate and extreme hypofractionation regimens show promising cancer control but long term results of noninferiority studies of both modalities are required before use in routine treatment as standard of care.
